Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry.
Several recent reports suggest that stearoyl-CoA desaturase 1 (SCD1), the rate-limiting enzyme in monounsaturated fatty acid synthesis, plays an important role in regulating lipid homeostasis and lipid oxidation in metabolically active tissues. As several manifestations of type 2 diabetes and related metabolic disorders are associated with alterations in intracellular lipid partitioning, pharmacological manipulation of SCD1 activity might be of benefit in the treatment of these disease states. In an effort to identify small molecule inhibitors of SCD1, we have developed a mass spectrometry based high-throughput screening (HTS) assay using deuterium labeled stearoyl-CoA substrate and induced rat liver microsomes. The methodology developed allows the use of a nonradioactive substrate which avoids interference by the endogenous SCD1 substrate and/or product that exist in the non-purified enzyme source. Throughput of the assay was up to twenty 384-well assay plates per day. The assay was linear with protein concentration and time, and was saturable for stearoyl-CoA substrate (K(m)=10.5 microM). The assay was highly reproducible with an average Z' value=0.6. Conjugated linoleic acid and sterculic acid, known inhibitors of SCD1, exhibited IC(50) values of 0.88 and 0.12 microM, respectively. High-throughput mass spectrometry screening of over 1.7 million compounds in compressed format demonstrated that the enzyme target is druggable. A total of 2515 hits were identified (0.1% hit rate), and 346 were confirmed active (>40% inhibition of total SCD activity at 20 microM--14% conformation rate). Of the confirmed hits 172 had IC(50) values of <10 microM, including 111 <1 microM and 48 <100 nM. A large number of potent drug-like (MW<450) hits representing six different chemical series were identified. The application of mass spectrometry to high-throughput screening permitted the development of a high-quality screening protocol for an otherwise intractable target, SCD1. Further medicinal chemistry and characterization of SCD inhibitors should lead to the development of reagents to treat metabolic disorders.
Soulard
Patricia
P
Research Technology Center, Pfizer Global Research and Development, Cambridge, MA, United States.
McLaughlin
Meg
M
Stevens
Jessica
J
Connolly
Brendan
B
Coli
Rocco
R
Wang
Leyu
L
Moore
Jennifer
J
Kuo
Ming-Shang T
MS
LaMarr
William A
WA
Ozbal
Can C
CC
Bhat
B Ganesh
BG
D000214:Acyl Coenzyme A / Q000378:metabolism*; D000818:Animals; D003521:Cyclopropanes / Q000494:pharmacology; D042966:Cytochrome-B(5) Reductase / Q000378:metabolism; D003903:Deuterium / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000201:enzymology; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology; D006801:Humans; D016014:Linear Models; D044243:Linoleic Acids, Conjugated / Q000494:pharmacology; D008297:Male; D013058:Mass Spectrometry; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology*; D051381:Rats; D054852:Small Molecule Libraries / Q000494:pharmacology; D013194:Staining and Labeling; D013230:Stearoyl-CoA Desaturase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013379:Substrate Specificity; D013997:Time Factors
D000214:Acyl Coenzyme A; D003521:Cyclopropanes; D004791:Enzyme Inhibitors; D005229:Fatty Acids, Monounsaturated; D044243:Linoleic Acids, Conjugated; D054852:Small Molecule Libraries; C017725:stearoyl-coenzyme A; D003903:Deuterium; D013230:Stearoyl-CoA Desaturase; D042966:Cytochrome-B(5) Reductase; C003345:sterculic acid